[1]李一君 谷伟军 王岳鹏 吕朝晖 母义明.4 276例垂体瘤的回顾性临床分析[J].国际内分泌代谢杂志,2022,42(01):7-11.[doi:10.3760/cma.j.cn121383-20211110-11036]
　Li Yijun,Gu Weijun,Wang Yuepeng,et al.Pituitary adenoma:retrospective clinical analysis of 4 276 cases[J].International Journal of Endocrinology and Metabolism,2022,42(01):7-11.[doi:10.3760/cma.j.cn121383-20211110-11036]
点击复制

4 276例垂体瘤的回顾性临床分析()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
42
期数:
2022年01期
页码:
7-11
栏目:
论著
出版日期:
2022-01-20

文章信息/Info

Title:
Pituitary adenoma:retrospective clinical analysis of 4 276 cases
作者:
李一君1 谷伟军1 王岳鹏1; 2 吕朝晖1 母义明1
1解放军总医院第一医学中心内分泌科,北京 100853; 2南开大学医学院,天津 300071
Author(s):
Li Yijun1;  Gu Weijun1;  Wang Yuepeng1; 2;  Lyu Zhaohui1;  Mu Yiming1.1
Department of Endocrinology, the First Medical Centre of PLA General Hospital, Beijing 100853, China; 2School of Medicine, Nankai University, Tianjin 300071, China
关键词:
垂体瘤;  临床特征;  激素分泌类型
Keywords:
Pituitary adenoma;  Clinical characteristics;  Hormone-secreting type
DOI:
10.3760/cma.j.cn121383-20211110-11036
摘要:
目的 总结不同激素分泌类型垂体瘤患者人群分布及临床特征,分析近16年垂体瘤疾病谱变化,指导临床诊疗。方法 收集2005年1月1日至2020年12月31日在解放军总医院第一医学中心首次住院诊疗的4 276例垂体瘤患者的病例资料,包括性别、年龄、入院日期、临床诊断、是否手术、术后病理诊断等,对其进行回顾性分析。结果(1)16年间就诊于解放军总医院第一医学中心的垂体瘤患者共4 276例,其中男性1 871例(占比43.76%),女性2 405例(占比56.24%),平均就诊年龄(44.1±13.9)岁。(2)垂体瘤以无功能瘤(占比60.67%)、泌乳素瘤(16.10%)、生长激素瘤(13.93%)居多,无功能瘤多集中于41～60岁人群,泌乳素瘤、生长激素瘤多集中于21～40岁人群。(3)随时间进展,垂体瘤患者住院例数呈现逐步增加的趋势,高峰出现在2012年,垂体生长激素瘤及垂体促肾上腺皮质激素瘤患者占比呈现逐年增加趋势,而无功能瘤患者占比呈现下降趋势。结论 垂体无功能瘤、泌乳素瘤、生长激素瘤仍是临床最常见的3种垂体瘤,住院垂体无功能瘤病例占比随时间进展呈现逐步下降趋势。
Abstract:
Objective To summarize the distribution and clinical characteristics of patients with pituitary adenoma of different hormone secreting types, analyze the changes of the disease spectrum and to guide clinical diagnosis and treatment.Methods All clinical data of patients with pituitary adenoma hospitalized in the First Medical Center of PLA General Hospital from Jan.1st 2005 to Dec.31rd 2020 were collected. The profile of gender ratio, age, date of admission, clinical diagnosis were retrospectively analyzed.Results A total of 4 276 patients with pituitary adenoma were treated during 16 years, including 1 871 males(43.8%)and 2 405 females(56.2%)with the average age of consultation was(44.1±13.9)years. Non-functioning adenoma(60.7%), prolactinoma(16.1%)and growth hormone adenoma(13.9%)were at relatively high proportion. The visiting age of non-functioning adenoma was mostly concentrated between 41～60 years, and prolactinoma and growth hormone adenoma were mostly concentrated between 21～40 years. The number of patients with pituitary adenoma gradually increased with a peak in 2012, while the proportion of patients with growth hormone adenoma and adrenocorticotropic hormone adenoma increased and the proportion of patients with non-functional adenoma decreased slightly.Conclusion Non-functional pituitary adenoma, prolactinoma, and growth hormone adenoma are still the most common pituitary adenoma in clinical practice. The proportion of hospitalized non-functional pituitary adenoma showes a gradual decline over time.

参考文献/References:

[1] Ostrom QT,Patil N,Cioffi G,et al.CBTRUS statistical report:primary brain and other central nervous system tumors diagnosed in the united states in 2013-2017[J].Neuro Oncol,2020,22(12 Suppl 2):iv1-iv96.DOI:10.1093/neuonc/noaa200.
[2] Theodros D,Patel M,Ruzevick J,et al.Pituitary adenomas:historical perspective,surgical management and future directions[J].CNS Oncol,2015,4(6):411-429.DOI:10.2217/cns.15.21.
[3] 张奇志,周印亭,汪莹,等.2010年-2018年1011例垂体瘤患者临床资料分析[J].世界最新医学信息文摘,2020,20(12):185-186.DOI:10.3969/j.issn.1671-3141.2020.12.120.
[4] 陈来照,马景鑑,郑安潮,等.128例垂体腺瘤回顾性分析[J].山西医科大学学报,2005,36(4):486-489.DOI:10.3969/j.issn.1007-6611.2005.04.036.
[5] 陈汉文,孙冰,孙海玲,等.287例垂体瘤患者临床特征分析及垂体功能评估[J].中华实用诊断与治疗杂志,2017,31(4):364-367.DOI:10.13507/j.issn.1674-3474.2017.04.015.
[6] 初曙光,沈天真,陈星荣.不同激素分泌类型垂体腺瘤的临床特点及MRI征象分析(附200例报告)[J].实用放射学杂志,2002,18(9):737-739.DOI:10.3969/j.issn.1002-1671.2002.09.001.
[7] Casanueva FF,Molitch ME,Schlechte JA,et al.Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas[J].Clin Endocrinol(Oxf),2006,65(2):265-273.DOI:10.1111/j.1365-2265.2006.02562.x.
[8] Boscaro M,Barzon L,Fallo F,et al.Cushing's syndrome[J].Lancet,2001,357(9258):783-791.DOI:10.1016/S0140-6736(00)04172-6.
[9] Arasho BD,Schaller B,Sandu N,et al.Gender-related differences in pituitary adenomas[J].Exp Clin Endocrinol Diabetes,2009,117(10):567-572.DOI:10.1055/s-0029-1202831.
[10] Tjörnstrand A,Gunnarsson K,Evert M,et al.The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011[J].Eur J Endocrinol,2014,171(4):519-526.DOI:10.1530/EJE-14-0144.
[11] Dolecek TA,Propp JM,Stroup NE,et al.CBTRUS statistical report:primary brain and central nervous system tumors diagnosed in the United States in 2005-2009[J].Neuro Oncol,2012,14 Suppl 5(Suppl 5):v1-49.DOI:10.1093/neuonc/nos218.
[12] Ostrom QT,Gittleman H,Liao P,et al.CBTRUS statistical report:primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014[J].Neuro Oncol,2017,19(suppl 5):v1-v88.DOI:10.1093/neuonc/nox158.

相似文献/References:

[1]许颖,孟令宇,郭静,等.男性垂体促性腺激素腺瘤5例报道并文献复习[J].国际内分泌代谢杂志,2015,(04):284.[doi:10.3760/cma.j.issn.1673-4157.2015.04.019]
　Xu Ying,Meng Lingyu,Guo Jing,et al.Cases report of five male gonadotroph adenoma and literatures review[J].International Journal of Endocrinology and Metabolism,2015,(01):284.[doi:10.3760/cma.j.issn.1673-4157.2015.04.019]
[2]刘海春 高洪波 李赟 李隆敏 邵玉军.基因突变对嗜铬细胞瘤/副神经节瘤临床特征及预后的影响[J].国际内分泌代谢杂志,2023,43(05):392.[doi:10.3760/cma.j.cn121383-20221029-10044]
　Liu Haichun,Gao Hongbo,Li Yun,et al.Effect of gene mutations on clinical features and prognosis of pheochromocytoma/paraganglioma[J].International Journal of Endocrinology and Metabolism,2023,43(01):392.[doi:10.3760/cma.j.cn121383-20221029-10044]

备注/Memo

备注/Memo:
通信作者:谷伟军,Email:guweijun301@163.com
更新日期/Last Update: 2022-01-20